-

Kathy Giusti, MMRF Founder & Chief Mission Officer, named recipient of American Association for Cancer Research Distinguished Public Service Award

Alongside Nancy Pelosi & Charles Sawyers

NORWALK, Conn.--(BUSINESS WIRE)--Kathy Giusti, MBA, Founder and Chief Mission Officer of the Multiple Myeloma Research Foundation and Co-Chair the Harvard Business School Kraft Precision Medicine Accelerator; Nancy P. Pelosi (D-California), Speaker of the U.S. House of Representatives; and Charles L. Sawyers, MD, FAACR, world-renowned cancer researcher and AACR Past President, received their awards virtually at the AACR Annual Meeting 2021 on April 11, 2021. The American Association for Cancer Research (AACR) presented Distinguished Public Service Awards to three individuals whose extraordinary work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, advocacy, and funding for cancer research.

“The AACR is extremely proud to present these Distinguished Public Service Awards to three highly accomplished individuals whose leadership and selfless dedication to scientific progress have helped countless cancer patients, survivors, and their families, both in the United States and around the world,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “We are grateful for their pioneering contributions to cancer research and biomedical science and look forward to celebrating them at the AACR Annual Meeting 2021.”

Of the award, Giusti commented, “I am incredibly honored - and humbled - to be the recipient of AACR’s 2021 Distinguished Public Service Award alongside exceptional leaders Nancy Pelosi & Charles Sawyers. As a 25-year cancer survivor, my life’s ambition is to speed up progress in finding ways to treat cancer – and to simplify the journey for patients and their loved ones. This award is a meaningful recognition of that and is to be shared with the Scientists, who work tirelessly to save lives and increase life expectancy. It is our duty to speed their unfinished work. There is too much hope on the horizon for us to slow down or give in.”

About the Multiple Myeloma Research Foundation (MMRF)

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 15 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised nearly $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.

For AACR information, visit Fast Facts.

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 48,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops—the largest of which is the AACR Annual Meeting, with more than 74,000 attendees for the 2020 virtual meetings and more than 22,500 attendees for past in-person meetings. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

Contacts

C.J. Volpe
Director, PR and Communications
Multiple Myeloma Research Foundation (MMRF)
203.652.0453
volpec@themmrf.org

Kate Walsh
917.580.1796
kate@ktwbrandconsulting.com

Multiple Myeloma Research Foundation

Details
Headquarters: Norwalk, CT
CEO: Michael Andreini
Employees: 50
Organization: NON

Release Summary
Kathy Giusti wins American Association for Cancer Research [AACR] Distinguished Public Service Award
Release Versions

Contacts

C.J. Volpe
Director, PR and Communications
Multiple Myeloma Research Foundation (MMRF)
203.652.0453
volpec@themmrf.org

Kate Walsh
917.580.1796
kate@ktwbrandconsulting.com

Social Media Profiles
More News From Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation Announces $21M Grant Program to Support Multicenter Translational Research Networks

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the MMRF’s urgent pursuit of a cure for each and every myeloma patient. “The MMRF makes signifi...

The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF). In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team. “We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael An...

MMRF Research Programs Expand Understanding of the Biology of Multiple Myeloma and Patient-Reported Outcomes in New Data Featured at the 20th IMS Annual Meeting

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠ datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023. Topics include: Multi-omic analysis of multiple myeloma subtypes based on samples from the MMRF CoMMpass Study Single-cell profiling in rapidly...
Back to Newsroom